Physician profile
Fauzia Paracha
NPI 1174639751
$15,329.27
in general payments reported to CMS, 2019-2025
51 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $2,497 · 2021: $2,696 · 2022: $2,544 · 2023: $2,678 · 2024: $2,208 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,416 · Education: $664 · Long Term Medical Supply Or Device Loan: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,416.40 |
| Education | $663.59 |
| Long Term Medical Supply Or Device Loan | $249.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,264.74 | 2019-2025 | |
| Janssen Biotech, INC. | $1,406.93 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $1,036.96 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $906.16 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Merck Sharp & Dohme LLC | $860.22 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $810.58 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Celgene Corporation | $579.05 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Amgen INC. | $500.87 | 2019-2023 | Kyprolis, Blincyto |
| Lilly USA, LLC | $397.68 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $392.27 | 2019-2025 | |
| Genentech USA, INC. | $299.28 | 2019-2025 | Venclexta |
| Puma Biotechnology, INC. | $279.34 | 2020-2025 | |
| Incyte Corporation | $255.20 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Ipsen Biopharmaceuticals, INC | $245.98 | 2019-2024 | Tazverik, Onivyde |
| Emd Serono, INC. | $213.39 | 2019-2024 | Bavencio |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $202.39 | 2020-2024 | Brukinsa |
| Genzyme Corporation | $190.46 | 2022-2025 | |
| Seagen INC. | $186.27 | 2019-2025 | Adcetris |
| Exelixis INC. | $168.29 | 2019-2023 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $153.36 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $145.00 | 2022-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.06 | 2019-2021 | |
| Array Biopharma INC | $130.47 | 2022-2024 | Braftovi, Mektovi, Lorbrena |
| Global Blood Therapeutics, INC. | $129.98 | 2020-2022 | |
| Astellas Pharma US INC | $122.51 | 2022-2025 | Xtandi, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $121.59 | 2019-2024 | Advate, Iclusig, Fruzaqla |
| Gilead Sciences, INC. | $118.55 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $109.68 | 2023-2025 | Enhertu |
| Eisai INC. | $107.23 | 2019-2024 | |
| Taiho Oncology, INC. | $105.31 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $73.35 | 2019-2023 | Imbruvica |
| Blueprint Medicines Corporation | $64.23 | 2022-2024 | Ayvakit |
| Glaxosmithkline, LLC. | $60.52 | 2022-2025 | Ojjaara, Jemperli |
| Genmab U.S., INC. | $54.48 | 2024-2025 | Tivdak |
| Janssen Pharmaceuticals, INC | $52.08 | 2022 | |
| Mirati Therapeutics, INC. | $51.81 | 2023-2024 | Krazati |
| Morphosys, US INC. | $47.84 | 2021-2023 | Monjuvi |
| Pharmaessentia USA Corporation | $45.54 | 2023-2024 | Besremi |
| Acrotech Biopharma INC. | $36.75 | 2021-2022 | |
| Adc Therapeutics America, INC. | $36.18 | 2024-2025 | |
| Myovant Sciences INC. | $30.42 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $28.38 | 2024 | |
| Karyopharm Therapeutics INC. | $24.88 | 2023 | Xpovio |
| Jazz Pharmaceuticals INC. | $22.97 | 2022 | |
| Rigel Pharmaceuticals, INC. | $21.69 | 2022 | |
| Kite Pharma, INC. | $20.61 | 2023 | Yescarta |
| Beone Medicines USA, INC. | $19.50 | 2025 | Brukinsa, Tevimbra |
| Amag Pharmaceuticals, INC. | $17.62 | 2021 | |
| Sobi, INC | $17.37 | 2024 | |
| Blue Earth Diagnostics | $17.29 | 2022 | |
| Tg Therapeutics, INC. | $14.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fauzia Paracha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.